5q-syndrome is a distinct form of myelodysplastic syndrome(MDS) where a deletion on chromosome 5 is the underlying *** is characterized by bone marrow failures,including macrocytic *** mapping and studies using vari...
详细信息
5q-syndrome is a distinct form of myelodysplastic syndrome(MDS) where a deletion on chromosome 5 is the underlying *** is characterized by bone marrow failures,including macrocytic *** mapping and studies using various models support the notion that ribosomal protein S14(RPS14) is the candidate gene for the erythroid *** disruption of RPS14 causes an increase in p53 activity and p53-mediated apoptosis,similar to what is observed with other ribosomal ***,due to the higher risk for cancer development in patients with ribosome deficiency,targeting the p53 pathway is not a viable treatment *** better understand the pathology of RPS14 deficiency in 5q-deletion,we generated a zebrafish model harboring a mutation in the RPS14 *** model mirrors the anemic phenotype seen in ***,the anemia is due to a late-stage erythropoietic defect,where the erythropoietic defect is initially p53-independent and then becomes ***,we demonstrate the versatility of this model to test various pharmacological agents,such as RAP-011,L-leucine,and dexamethasone in order to identify molecules that can reverse the anemic phenotype.
Cancer trials often start investigational therapy at diagnosis or after a selected number of *** are the usual core inclusion criteria in clinical *** it is helpful when planning a trial to know the likely percentages...
详细信息
Cancer trials often start investigational therapy at diagnosis or after a selected number of *** are the usual core inclusion criteria in clinical *** it is helpful when planning a trial to know the likely percentages of patients receiving standard therapy at clinics and hospitals who meet this key inclusion criteria of being newly diagnosed during a period or having just had their first,second or third relapse during an anticipated enrollment time *** regulatory agencies will have approvals tied to the use of a therapy in a relapsed context or in a newly diagnosed *** provide details on calculations to help those in clinical trial operations make realistic assessments on the number of sites and likely enrollment at clinical trial sites,and the enrollment time frames that might be needed to complete planned total patient *** estimates complement site feasibility questionnaires which are often sent to gauge patient availability and site interest.
暂无评论